Analysts’ top 10 biotech takeover targets are concentrated in two key areas
CEO Schwan of Swiss drugmaker Roche addresses the annual news conference in Basel Getty
While Credit Suisse was sizing up the amount of overseas money that will soon be available to the top buyers in biopharma, their analysts put together a list of top takeover targets, ranked by market cap. I’m pulling out the top 10 here to go alongside the main story — for Endpoints News Insiders — on who has $171 billion to play with, along with suggestions on how they can spend that money.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.